Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
blood count
breast cancer care
inflammatory biomarkers
neoadjuvant chemotherapy
prognostic factors
tailored therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
27 Oct 2022
27 Oct 2022
Historique:
received:
14
09
2022
revised:
20
10
2022
accepted:
24
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
12
11
2022
Statut:
epublish
Résumé
Immune inflammatory biomarkers are easily obtained and inexpensive blood-based parameters that recently showed prognostic and predictive value in many solid tumors. In this study, we aimed to investigate the role of these biomarkers in predicting distant relapse in breast cancer patients treated with neoadjuvant chemotherapy (NACT). All breast cancer patients who referred to our Breast Unit and underwent NACT were retrospectively reviewed. The pre-treatment neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), and pan-immune-inflammation value (PIV) were calculated from complete blood counts. The primary outcome was 5-year distant-metastasis-free survival (DMFS). In receiver operating characteristic analyses, the optimal cutoff values for the NLR, PLR, MLR, and PIV were determined at 2.25, 152.46, 0.25, and 438.68, respectively. High levels of the MLR, but not the NLR, PLR, or PIV, were associated with improved 5-year DMSF in the study population using both univariate (HR 0.52,
Identifiants
pubmed: 36358706
pii: cancers14215287
doi: 10.3390/cancers14215287
pmc: PMC9658892
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Breast Cancer Res Treat. 2021 Jan;185(1):63-72
pubmed: 32948994
Sci Rep. 2016 Oct 27;6:36107
pubmed: 27786298
Drugs Context. 2022 Jun 28;11:
pubmed: 35855461
Curr Opin Clin Nutr Metab Care. 2009 May;12(3):223-6
pubmed: 19318937
Cancer Biol Ther. 2020;21(2):189-196
pubmed: 31684807
Clin Breast Cancer. 2020 Aug;20(4):e403-e409
pubmed: 32201163
PLoS One. 2016 Jul 29;11(7):e0153459
pubmed: 27472762
Curr Oncol. 2018 Apr;25(2):e113-e119
pubmed: 29719435
Oncotarget. 2017 Jan 3;8(1):1023-1030
pubmed: 27906679
Sci Rep. 2020 Aug 4;10(1):13078
pubmed: 32753659
Cells. 2021 Jul 03;10(7):
pubmed: 34359855
BMJ Open. 2021 Sep 24;11(9):e047957
pubmed: 34561257
PLoS One. 2018 Jul 26;13(7):e0200936
pubmed: 30048474
Front Immunol. 2020 Jul 08;11:1444
pubmed: 32733479
Cancers (Basel). 2020 Apr 13;12(4):
pubmed: 32295078
Cancer Med. 2019 Aug;8(9):4135-4148
pubmed: 31197958
Anticancer Res. 2015 Sep;35(9):5037-46
pubmed: 26254405
Sci Rep. 2021 Jul 19;11(1):14662
pubmed: 34282214
Front Oncol. 2022 Apr 13;12:830138
pubmed: 35494034
World J Surg. 2012 Mar;36(3):617-22
pubmed: 22223293
Front Oncol. 2022 Feb 11;11:827625
pubmed: 35223459
Bratisl Lek Listy. 2001;102(1):5-14
pubmed: 11723675
PLoS One. 2018 Nov 14;13(11):e0207224
pubmed: 30427884
Breast Cancer Res. 2017 Jan 5;19(1):2
pubmed: 28057046
Braz J Med Biol Res. 2021 Aug 13;54(10):e11409
pubmed: 34406210
Biomedicines. 2022 May 29;10(6):
pubmed: 35740290
Oncol Lett. 2019 Dec;18(6):6275-6283
pubmed: 31788105
Clin Transl Oncol. 2019 Jul;21(7):855-863
pubmed: 30506134
Blood. 2013 Nov 21;122(22):3666-77
pubmed: 24113869
Front Oncol. 2021 Nov 04;11:773078
pubmed: 34804977